Key result
ASA increases thrombus detachment ~4-fold versus control despite little effect on high shear occlusion times.
Why the study?
How do different shear rates and antiplatelet therapy doses affect occlusion times and thrombus detachment in a microfluidic model?
How do different shear rates and antiplatelet therapy doses affect occlusion times and thrombus detachment in a microfluidic model?
In a microfluidic model, shear rate significantly impacts the efficacy of antiplatelet therapies, with ASA showing limited effect on high shear occlusion but increasing thrombus detachment, while eptifibatide effectively reduces occlusion.
No takes yet. Share an insight, caveat, or question.
High-shear ASA inefficacy cautions against uniform dosing; leaves open shear-tailored antiplatelet trials.
Li et al. (2014) studied Thrombosis. Eptifibatide, acetyl-salicylic acid (ASA), and heparin vs. Control conditions was evaluated on Occlusion times and thrombus detachment. Shear rates significantly affected thrombosis dose-response curves, with ASA having little effect on high shear occlusion times but increasing thrombus detachment 4-fold compared to control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: